Comparison of clinical features and outcomes in COVID-19 and influenza pneumonia patients requiring intensive care unit admission
Open Access
- 26 May 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Infection
- Vol. 49 (5), 965-975
- https://doi.org/10.1007/s15010-021-01624-7
Abstract
Background Little is known in distinguishing clinical features and outcomes between coronavirus disease-19 (COVID-19) and influenza (FLU). Materials/methods Retrospective, single-centre study including patients with COVID-19 or FLU pneumonia admitted to the Intensive care Unit (ICU) of Policlinico Umberto I (Rome). Aims were: (1) to assess clinical features and differences of patients with COVID-19 and FLU, (2) to identify clinical and/or laboratory factors associated with FLU or COVID-19 and (3) to evaluate 30-day mortality, bacterial superinfections, thrombotic events and invasive pulmonary aspergillosis (IPA) in patients with FLU versus COVID-19. Results Overall, 74 patients were included (19, 25.7%, FLU and 55, 74.3%, COVID-19), median age 67 years (58–76). COVID-19 patients were more male (p = 0.013), with a lower percentage of COPD (Chronic Obstructive Pulmonary Disease) and chronic kidney disease (CKD) (p = 0.001 and p = 0.037, respectively) than FLU. SOFA score was higher (p = 0.020) and lymphocytes were significantly lower in FLU than in COVID-19 [395.5 vs 770.0 cells/mmc, p = 0.005]. At multivariable analysis, male sex (OR 6.1, p < 0.002), age > 65 years (OR 2.4, p = 0.024) and lymphocyte count > 725 cells/mmc at ICU admission (OR 5.1, p = 0.024) were significantly associated with COVID-19, whereas CKD and COPD were associated with FLU (OR 0.1 and OR 0.16, p = 0.020 and p < 0.001, respectively). No differences in mortality, bacterial superinfections and thrombotic events were observed, whereas IPA was mostly associated with FLU (31.5% vs 3.6%, p = 0.0029). Conclusions In critically ill patients, male sex, age > 65 years and lymphocytes > 725 cells/mmc are related to COVID-19. FLU is associated with a significantly higher risk of IPA than COVID-19.Keywords
Funding Information
- Università degli Studi di Roma La Sapienza
This publication has 50 references indexed in Scilit:
- Diagnosing COVID-19-associated pulmonary aspergillosisThe Lancet Microbe, 2020
- COVID‐19 associated pulmonary aspergillosisMycoses, 2020
- Clinical and virological data of the first cases of COVID-19 in Europe: a case seriesThe Lancet Infectious Diseases, 2020
- Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort studyThe Lancet, 2020
- Clinical significance of lymphocytopenia in patients hospitalized with pneumonia caused by influenza virusCritical Care, 2019
- Survival during influenza-associated bacterial superinfection improves following viral- and bacterial-specific monoclonal antibody treatmentJCI Insight, 2019
- Intensive care management of influenza-associated pulmonary aspergillosisClinical Microbiology & Infection, 2019
- MONITORING OF PARTICLE ENVIRONMENTAL POLLUTION AND FUNGAL ISOLATIONS DURING HOSPITAL BUILDING-WORK ACTIVITIES IN A HEMATOLOGY WARD.Mediterranean Journal of Hematology and Infectious Diseases, 2019
- Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: a retrospective cohort studyThe Lancet Respiratory Medicine, 2018
- Invasive pulmonary aspergillosis in heart transplant recipients: Two radiologic patterns with a different prognosisThe Journal of Heart and Lung Transplantation, 2014